Status:
COMPLETED
Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC)
Lead Sponsor:
The First Hospital of Hebei Medical University
Conditions:
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This prospective, randomized controlled trial investigates the efficacy of a targeted dietary intervention in patients with hepatocellular carcinoma (HCC). The study aims to compare a structured diet ...
Detailed Description
Hepatocellular carcinoma (HCC) is associated with gut microbiota dysbiosis, which contributes to a pro-inflammatory and immunosuppressive tumor microenvironment via the "gut-liver axis." This study hy...
Eligibility Criteria
Inclusion
- Age between 18 and 80 years.
- Pathologically confirmed primary Hepatocellular Carcinoma (HCC).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Adequate organ function (e.g., liver, renal, and bone marrow).
- Life expectancy of at least 3 months.
- Willingness to provide informed consent and adhere to study procedures.
Exclusion
- Concurrent malignancies other than HCC.
- Severe, uncontrolled comorbidities (e.g., congestive heart failure, renal failure).
- Known history of severe intestinal diseases such as inflammatory bowel disease.
- Use of antibiotics, probiotics, or other microbiota-altering agents within 4 weeks prior to enrollment.
- Cognitive impairment precluding understanding of the study.
- Refusal to provide consent.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07143955
Start Date
May 1 2022
End Date
September 30 2023
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050000